Loading company
JNJJohnson & Johnson$674.9BA+Just reported
From ELI Lilly's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$24.4B
+39% y/y
+6.2% q/q
Guided
—
No guide given
Actual
$7.22
+16% y/y
-9.1% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Shares of revenue are estimates for year ended December 31, 2025, not figures from a filing.
Mounjaro
A medicine used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Zepbound
A medicine for adults with obesity, or overweight with a weight-related health condition. It is also approved for certain adults with obesity and moderate to severe sleep apnea.
Foundayo (orforglipron)
An oral medicine approved in the United States for obesity. Lilly has also submitted it for review as a treatment for type 2 diabetes.
Verzenio
A medicine used alone or with hormone treatment for certain adults with hormone receptor-positive breast cancer.
Jardiance
A medicine used for type 2 diabetes and to reduce certain risks related to heart failure and chronic kidney disease. Lilly markets it in collaboration with Boehringer Ingelheim.
Trulicity
A medicine for type 2 diabetes in adults and some children, and to reduce the risk of certain heart problems in some adults with type 2 diabetes.
Lilly researches, develops, manufactures, and sells human medicines in the United States and around the world. Its medicines treat conditions including type 2 diabetes, obesity, cancer, inflammatory diseases, migraine, and Alzheimer's disease. It also works with other companies on research, development, and marketing of some medicines.
Built from ELI Lilly & Co’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes ELI Lilly is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$1,437.79+0.3%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
Company outlook: revenue of $91B to $92B for Fiscal year 2026 — up 40.4% on a year earlier
Grade A+
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of ELI Lilly & Co’s grade history. The other 39 go back to October 2016.
